Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of
a global pandemic that has led to more than 2 million deaths worldwide. The Moderna …

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …

The number and variability of the neutralizing epitopes targeted by polyclonal antibodies in
individuals who are SARS-CoV-2 convalescent and vaccinated are key determinants of …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …

The sensitivity of SARS-CoV-2 variants of concern (VOCs) to neutralizing antibodies has
largely been studied in the context of key receptor binding domain (RBD) mutations …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Small number of SARS-CoV-2 epidemic lineages did not efficiently exhibit a neutralization
profile, while single amino acid mutation in the spike protein has not been confirmed in …

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2.
However, ongoing surveillance has revealed the emergence of variants harboring mutations …

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible
decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA …